Organisation of European Cancer Institutes

Short Name: OECI

Country: BE


Organization description:

The OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979 and  remodelled in 2005 into OECI-EEIG, a European Economic Interest Grouping.

Today, the OECI regroups 93 Members, which include some of the most prominent European Comprehensive Cancer Centres. Several major cancer centres from the Russian Federation, Turkey, Ukraine and Latin America are also members of our Organisation in order to benefit from our Accreditation and Designation Programme


The OECI aims to promote efficient partnership, reduce fragmentation and increase competitiveness amongst European cancer centres and institutes. This goal is being achieved by promoting and enhancing the concept of “comprehensiveness” and “multidisciplinarity”, supporting quality in cancer care and dynamically working in crosscut expertise by involving our Working Groups, our Members and promoting synergies with other cancer Organisations.

The OECI is currently geared towards creating a “network of cancer networks” where primary prevention, screening & early diagnosis, basic, translational & clinical research, collaboration for good practices with patients, biobanks and pathobiology, supportive and palliative care, cancer economics and centralising real-life cancer patient data are included.

The above goal is part of the Presidential proposal of an OECI evolution that may better answer to the need to work on a European Cancer Mission within the incoming Framework Programme “Horizon Europe”.

The OECI aim is to accelerate the application of multidisciplinary personalised care approaches, to reduce morbidity and to guarantee an equitable access to care to all cancer patients, avoiding the collapse of the National Health Systems all over Europe.


OECI Liaison Office OECI Central Office

Accreditation and Designation Programme Biobanks and Molecular Pathobiology WG Cancer Economics and Benchmarking WG Cancer Outcomes Research WG Supportive and Palliative Care WG

Collaboration for Good Practices with Patients WG Communication and Dissemination Activity WG


Other European projects:


OECI is participating as a partner to the Joint Action on Rare Cancers « JARC » Project ID: 724161

Call: HP-ADHOC-2014-2020-JA-2015

OECI is also involved as sub-contractor to the Joint Action Innovative Partnership on Action against Cancer (JA-02-2017) “ iPAAC »

Role in the project:

To develop the activities of validation, communication and dissemination within WP5. OECI has a great expertise in communication and dissemination tools.

The following instrument will be adopted:

  • OECI website
  • OECI Magazine – bi-annual Published by OECI
  • OECI Yearbook published each year and containing special announcement related to the main activities/project where the Organisation is involved
  • Specific publication of ecancer, the OECI Official online Journal that provides the healthcare community with a vast online library of free educational resources covering every disease type, available at The Journal is a completely free online knowledge bank incorporating an open-access journal, news, video, and e-learning (in both English and Spanish), medical education events all over the world, helping to connect the healthcare community to practice changing
  • OECI direct contact with all its members
  • Specific Sessions or round tables at the Annual OECI Event: OECI Oncology Days
  • Communicaitons sent to the European ancer Orgnaisation
  • Specific pages published on Cancerworld
  • Scientific papers     published     on     the     OECI        affiliated      Review      “Tumori       Journal”,

Concerning the validation process, OECI has already discussed a process of rapid validation of biomarkers, targets and methods through the collaboration of OECI Certified Comprehensive Cancer Centres and Clinical Cancer Centres.

Key personnel:


Prof. Giorgio Stanta of the University of Trieste

He is an expert in molecular pathology and diagnostics for oncology on the European level. He is involved in many European organizations:

  • He is the coordinator of the European group “Archive Tissues: Improving Molecular Medicine Research and Clinical Practice – IMPACTS” (
  • He is the chairman of the “Biobanking and Molecular Pathobiology Working Group” of the OECI (Organisation of European Cancer Institutes –
  • He is the vice-chairman of the “Molecular Pathology Working Group” of the ESP (European Society of Pathology –
  • He is a member of the managing board of BBMRI.IT (Italian Biobanking Infrastructure).
  • He is the liaison representative from the European Society of Pathology to CEN/TC 140.
  • He is a member of the European Commission Initiative on Breast Cancer – Quality Assurance Scheme Development Group (QASDG), in which he is the Chair of the Clinical Research Subgroup.
  • He is involved in the active European projects such as HERCULES on High Grade Serus Ovary Carcinoma, and SPIDIA4P project of QIAGEN on Preanalytical Conditions of Tissues and MEMS (Italy-Austria Interreg project).
  • He is in charge for the development of the European Molecular Pathology Master.

Prof. Claudio Lombardo – OECI Director

CEO and Scientific Director of “SOS Europe Srl”

Director of the Organisation of European Cancer Institutes (OECI)

Visiting professor at the University of Medicine and Pharmacy of Cluj Napova – Romania

Secretary General of the no profit association Pro-IST

Legal Entity Appointed Representative (LEAR) of the OECI

Legal Entity Appointed Representative (LEAR) of the SOS Europe Srl

Main publications and patents:

Main publications and awards:



Stanta G, Bonin S. Overview on Clinical Relevance of Intra-Tumor Heterogeneity. Front Med (Lausanne). 2018 Apr 6;5:85. doi:

10.3389/fmed.2018.00085. eCollection 2018. Review. PubMed PMID: 29682505; PubMed Central PMCID: PMC5897590.

Borisch B, Stanta G. Clinical Relevance of Intra-Tumour Heterogeneity. Pathobiology. 2018;85(1-2):5-6. doi: 10.1159/000488788. Epub 2018 Apr 11. PubMed PMID: 29642072.

Demlova R, Zdrazilova-Dubska L, Sterba J, Stanta G, Valik D. Host-dependent variables: The missing link to personalized medicine. Eur J Surg Oncol. 2018 Sep;44(9):1289-1294. doi: 10.1016/j.ejso.2018.04.014. Epub 2018 Apr 26. Review. PubMed PMID: 29735363.

Bonin S, Parascandolo A, Aversa C, Barbazza R, Tsuchida N, Castellone MD, Stanta G, Vecchio G. Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients. Oncotarget. 2018 Feb 7;9(20):15228-15238. doi:

10.18632/oncotarget.24445. eCollection 2018 Mar 16. PubMed PMID: 29632639; PubMed Central PMCID: PMC5880599.

De Monte A, Brunetti D, Cattin L, Lavanda F, Naibo E, Malagoli M, Stanta G, Bonin S. Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. Mol Clin Oncol. 2018 Mar;8(3):504-512. doi: 10.3892/mco.2018.1554. Epub 2018 Jan 11. PubMed PMID: 29456855; PubMed Central PMCID: PMC5795555.

Silvestris N, Ciliberto G, De Paoli P, Apolone G, Lavitrano ML, Pierotti MA, Stanta G; On the behalf of the “dynamic medicine OECI group”. Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology  research. J Exp Clin Cancer Res. 2017 Sep 13;36(1):128. doi:

10.1186/s13046-017-0598-x. Review. PubMed PMID: 28903768; PubMed Central PMCID: PMC5598055.

Stanta G, Bonin S. A Practical Approach to Tumor Heterogeneity in Clinical Research and Diagnostics. Pathobiology. 2018;85(1-2):7-17. doi: 10.1159/000477813. Epub 2017 Jul 28. PubMed PMID: 28750401.

Gulei D, Mehterov N, Ling H, Stanta G, Braicu C, Berindan-Neagoe I. The

“good-cop bad-cop” TGF-beta role in breast cancer modulated by non-coding RNAs. Biochim Biophys Acta Gen Subj. 2017 Jul;1861(7):1661-1675. doi: 10.1016/j.bbagen.2017.04.007. Epub 2017 Apr 11. Review. PubMed PMID: 28411077.

Doucet M, Becker KF, Björkman J, Bonnet J, Clément B, Daidone MG, Duyckaerts C, Erb G, Haslacher H, Hofman P, Huppertz B, Junot C, Lundeberg J, Metspalu A, Lavitrano M, Litton JE, Moore HM, Morente M, Naimi BY, Oelmueller U, Ollier B, Parodi B, Ruan L, Stanta G, Turano P, Vaught J, Watson P, Wichmann HE, Yuille M, Zaomi M, Zatloukal K, Dagher G. Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking. Biopreserv Biobank. 2017

Jun;15(3):270-276. doi: 10.1089/bio.2016.0053. Epub 2016 Dec 19. PubMed PMID: 27992240; PubMed Central PMCID: PMC5586151.

Pascale M, Aversa C, Barbazza R, Marongiu B, Siracusano S, Stoffel F, Sulfaro S, Roggero E, Bonin S, Stanta G. The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients. Radiol Oncol. 2016 Jul 19;50(3):313-20. doi: 10.1515/raon-2016-0033. eCollection 2016 Sep 1. PubMed PMID: 27679548; PubMed Central PMCID: PMC5030813.

Caruso P, Naccarato M, Faoro V, Pracella D, Borando M, Dotti I, Koscica N, Stanta G, Pizzolato G, Manganotti P. Expression of the Endocannabinoid Receptor 1 in Human Stroke: An Autoptic Study. J Stroke Cerebrovasc Dis. 2016 Sep;25(9):2196-202. doi: 10.1016/j.jstrokecerebrovasdis.2016.03.006. Epub 2016 Jul 15. PubMed PMID: 27425766.

Stanta G, Jahn SW, Bonin S, Hoefler G. Tumour heterogeneity: principles and practical consequences. Virchows Arch. 2016 Oct;469(4):371-84. doi: 10.1007/s00428-016-1987-9. Epub 2016 Jul 13. Review. PubMed PMID: 27412632.

Bonin S, Donada M, Bussolati G, Nardon E, Annaratone L, Pichler M,

Chiaravalli AM, Capella C, Hoefler G, Stanta G. A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients. Tumour Biol. 2016 Jun;37(6):7295-303. doi: 10.1007/s13277-015-4543-3.

Epub 2015 Dec 15. PubMed PMID: 26666825.

Bonin S, Pracella D, Barbazza R, Sulfaro S, Stanta G. In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8  expression in lymph node metastases but not in the primary tumour is an indicator of better survival. Virchows Arch. 2015 May;466(5):571-80. doi:

10.1007/s00428-015-1748-1. Epub 2015 Feb 28. PubMed PMID: 25724181.

Stanta G. Tissue Heterogeneity as a Pre-analytical Source of Variability. Recent Results Cancer Res. 2015;199:35-43. doi: 10.1007/978-3-319-13957-9_4. PubMed PMID: 25636427.

Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjö A, Rouleau E, Solé F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH; European Society of Pathology Task Force on Quality Assurance in Molecular Pathology; Royal College of Pathologists. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014 Nov;67(11):923-31. doi: 10.1136/jclinpath-2014-202404. Epub 2014 Jul 10. Review. PubMed PMID: 25012948; PubMed Central PMCID: PMC4215286.

Pascale M, Pracella D, Barbazza R, Marongiu B, Roggero E, Bonin S, Stanta G. Is human papillomavirus associated with prostate cancer survival? Dis Markers.

2013;35(6):607-13. doi: 10.1155/2013/735843. Epub 2013 Oct 30. PubMed PMID:

24288430; PubMed Central PMCID: PMC3830784

Pracella D, Bonin S, Barbazza R, Sapino A, Castellano I, Sulfaro S, Stanta G.

Are breast cancer molecular classes predictive of survival in patients with long

follow-up? Dis Markers. 2013;35(6):595-605. doi: 10.1155/2013/347073. Epub 2013 Oct 30. PubMed PMID: 24288429; PubMed Central PMCID: PMC3830786.

Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R,

Romano G, Masiero L, Leone BE, Bonin S, Donada M, Stanta G, Helin K, Lavitrano M.

Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy. Clin Cancer Res. 2013 Jul

15;19(14):3820-31. doi: 10.1158/1078-0432.CCR-12-3289. Epub 2013 May 31. PubMed PMID: 23729362.

Bonin S, Stanta G. Nucleic acid extraction methods from fixed and paraffin-embedded tissues in cancer diagnostics. Expert Rev Mol Diagn. 2013

Apr;13(3):271-82. doi: 10.1586/erm.13.14. Review. PubMed PMID: 23570405.

Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G. Management of stage II colon cancer – the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol. 2013 Feb 27;13:36. doi: 10.1186/1471-230X-13-36. PubMed PMID: 23446022; PubMed Central PMCID: PMC3599045.

Buda A, De Bona M, Dotti I, Piselli P, Zabeo E, Barbazza R, Bellumat A, Valiante F, Nardon E, Probert CS, Pignatelli M, Stanta G, Sturniolo GC, De Boni M. Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy. Clin Transl Gastroenterol. 2012 Jan 5;3:e6. doi: 10.1038/ctg.2011.5. PubMed PMID: 23238028; PubMed Central PMCID: PMC3365671.

Faoro V, Barbazza R, Bonin S, Brunetti D, Sulfaro S, Stanta G. Detection of HPV E7 oncoviral protein in cervical lesions by a new antibody. Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):341-50. doi: 10.1097/PAI.0b013e318269bf5d. PubMed PMID: 22935825.

Pavlidis N, Stanta G, Audisio RA. Cancer prevalence and mortality in centenarians: a systematic review. Crit Rev Oncol Hematol. 2012 Jul;83(1):145-52. doi: 10.1016/j.critrevonc.2011.09.007. Epub 2011 Oct 22. Review. PubMed PMID: 22024388

Mendoza-Maldonado R, Faoro V, Bajpai S, Berti M, Odreman F, Vindigni M, Ius T, Ghasemian A, Bonin S, Skrap M, Stanta G, Vindigni A. The human RECQ1 helicase is highly expressed in glioblastoma and plays an important role in tumor cell proliferation. Mol Cancer. 2011 Jul 13;10:83. doi: 10.1186/1476-4598-10-83. PubMed PMID: 21752281; PubMed Central PMCID: PMC3148559.

Stanta G, Bonin S, Machado I, Llombart-Bosch A. Models of biobanking and tissue preservation: RNA quality in archival samples in pathology laboratories and “in vivo biobanking” by tumor xenografts in nude mice-two models of quality assurance in pathology. Biopreserv Biobank. 2011 Jun;9(2):149-55. doi: 10.1089/bio.2011.0010. PubMed PMID: 24846260.

Bonin S, Larese FF, Trevisan G, Avian A, Rui F, Stanta G, Bovenzi M. Gene expression changes in peripheral blood mononuclear cells in occupational exposure to nickel. Exp Dermatol. 2011 Feb;20(2):147-8. doi:

10.1111/j.1600-0625.2010.01162.x. Epub 2010 Nov 5. PubMed PMID: 21054559.

Nardon E, Glavač D, Benhattar J, Groenen PJ, Höfler G, Höfler H, Jung A, Keller G, Kirchner T, Lessi F, Ligtenberg MJ, Mazzanti CM, Winter G, Stanta G. A multicenter study to validate the reproducibility of MSI testing with a panel of

quasimonomorphic mononucleotide repeats. Diagn Mol Pathol. 2010

Dec;19(4):236-42. doi: 10.1097/PDM.0b013e3181db67af. PubMed PMID: 21051996.

Bonin S, Hlubek F, Benhattar J, Denkert C, Dietel M, Fernandez PL, Höfler G, Kothmaier H, Kruslin B, Mazzanti CM, Perren A, Popper H, Scarpa A, Soares P, Stanta G, Groenen PJ. Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch. 2010 Sep;457(3):309-17. doi:

10.1007/s00428-010-0917-5. Epub 2010 Jul 28. PubMed PMID: 20665046; PubMed Central PMCID: PMC2933807.

Dotti I, Bonin S, Basili G, Nardon E, Balani A, Siracusano S, Zanconati F, Palmisano S, De Manzini N, Stanta G. Effects of formalin, methacarn, and fineFIX fixatives on RNA preservation. Diagn Mol Pathol. 2010 Jun;19(2):112-22. doi: 10.1097/PDM.0b013e3181b520f8. PubMed PMID: 20502189.

Bonin S, Tothova SM, Barbazza R, Brunetti D, Stanta G, Trevisan G. Evidence of multiple infectious agents in mycosis fungoides lesions. Exp Mol Pathol. 2010 Aug;89(1):46-50. doi: 10.1016/j.yexmp.2010.05.001. Epub 2010 May 12. PubMed PMID: 20470773.

Donada M, Bonin S, Nardon E, De Pellegrin A, Decorti G, Stanta G. Thymidilate synthase expression predicts longer survival in patients with stage II colon

cancer treated with 5-flurouracil independently of microsatellite instability. J Cancer Res Clin Oncol. 2011 Feb;137(2):201-10. doi: 10.1007/s00432-010-0872-1. Epub 2010 Apr 13. PubMed PMID: 20387074.

Bevilacqua G, Bosman F, Dassesse T, Höfler H, Janin A, Langer R, Larsimont D, Morente MM, Riegman P, Schirmacher P, Stanta G, Zatloukal K, Caboux E, Hainaut P. The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch. 2010 Apr;456(4):449-54. doi: 10.1007/s00428-010-0887-7.

Epub 2010 Feb 16. Review. PubMed PMID: 20157825; PubMed Central PMCID: PMC2852521.

Prof. Giorgio Stanta published as editor the issue “Clinical Relevance of Intra-Tumour Heterogeneity” of the scientific journal Pathobiology (see point 2:).

In 2011, he also wrote and published for Springer the book “Guidelines for Molecular Analysis in Archive Tissues”.


Claudio Lombardo

2003      Winner of the Fondazione Carive Prize 2002 with the “Biolumitech” project 2006                             Dubbed the decoration: “Commendatore della Repubblica Italiana